鉻（三價鉻） Chromium × 多囊性卵巢症候群
結論：證據分歧
鉻 × PCOS 之證據為「機轉合理 + 少量小型 RCT」典型 C 級情境。
C 🟠 C 薄弱證據 證據分歧 ✨ low — community discussion mostly non-commercial
鉻 × PCOS 之證據為「機轉合理 + 少量小型 RCT」典型 C 級情境。
L1 Examine 雖列出多項 grade B 結果（Excessive Hair Growth、BMI、Insulin、Free Testosterone 等，n=351 across 3 RCTs primary），但 L2 PubMed 明確指出三篇 2017-2018 系統性回顧（Tang n=351、Heshmati n=286、Maleki n=274）高度重疊同一批伊朗單中心試驗（Jamilian/Asemi 系列），效應規模偏小（BMI WMD -0.87 至 -1.13 kg/m²、Insulin WMD -1.31 mIU/L），且無 n>200 獨立 RCT、無 Cochrane SR；兩篇基礎先導 RCT（Lucidi 2005 n=6、Lydic 2006 n=5）嚴重 underpowered。
L5 五大權威中無一推薦：Harvard 引用 6 RCT 系統性回顧明確指鉻補充對 PCOS 體重/血糖無效（not_supportive），Cleveland 在 2023 專文〈Skip the Supplement〉指 PCOS 早期結果「沒有經得起時間考驗」（cautious-against），Mayo 與 ASRM/Endocrine Society 2023 國際 PCOS 指引完全未提鉻（only inositol 被論述），NIH ODS 標記 PCOS 為 insufficient/not directly addressed。
L1 grade B 與 L5 主流共識之間存在實質落差：Examine 的 B 級反映「pooled surrogate 信號存在」，但 society/權威層級判定「證據基礎尚不足以推薦」。
整合判讀：弱正向 surrogate 訊號（C 偏 C+），不到 B；遠不到 D（不是反證據，是證據強度不足以支持常規補充）。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.56
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 證據分歧
信心度
61%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.556
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Effect of chromium supplementation on metabolic profiles in PCOS: A systematic review and meta-analysis of RCTs
結論：Chromium significantly reduced insulin (WMD -1.31 mIU/L, 95%CI -2.42 to -0.21), HOMA-IR (WMD -0.34, 95%CI -0.65 to -0.04) and BMI (WMD -0.87 kg/m2); no significant effect on fasting glucose, total testosterone, or lipid sub-fractions; trend toward improved hirsutism (Ferriman-Gallwey).
前往 PubMed
The Influences of Chromium Supplementation on Glycemic Control, Markers of Cardio-Metabolic Risk, and Oxidative Stress in Infertile Polycystic ovary Syndrome Women Candidate for In vitro Fertilization: a Randomized, Double-Blind, Placebo-Controlled Trial
結論：Pooled analysis showed chromium reduced BMI (WMD -1.13, 95%CI -2.06 to -0.20), free testosterone (WMD -1.05 pg/mL, 95%CI -1.93 to -0.17) and increased free fatty acids; no effect on insulin, HOMA-IR, glucose or oxidative stress markers in pooled analysis. Heterogeneity high.
前往 PubMed
Chromium supplementation and polycystic ovary syndrome: A systematic review and meta-analysis
結論：Chromium picolinate appears to improve insulin sensitivity, BMI and ovulation in PCOS patients but findings limited by small samples and heterogeneous dosing; suggests potential adjunct role but evidence not yet definitive.
前往 PubMed
Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
結論：Chromium significantly decreased free testosterone (-0.7 vs +0.1 pg/mL, p=0.02), hs-CRP (p=0.02), MDA (p=0.01) and increased GSH (p=0.01) and TAC (p=0.04) vs placebo; no effect on SHBG or other androgens.
前往 PubMed
Comparing the effect of metformin and chromium picolinate on PCOS: a randomized clinical trial (Amooee)
結論：Both arms produced significant improvement in BMI, fasting insulin and ovulation rate; metformin superior on FSH/LH normalization while chromium showed comparable effects on insulin sensitivity and BMI with better tolerability; both agents improved ovulation (p<0.05 within group).
前往 PubMed
Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome (Lydic)
結論：Chromium picolinate 1000 mcg/d improved glucose disposal rate by 38% (p<0.05) in obese PCOS women; pilot study with very small n; no effect on ovulation/menstrual frequency in 8 weeks.
前往 PubMed
Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome
結論：Chromium picolinate 200 mcg/d for 16 weeks improved insulin sensitivity (M-value) by 35% in PCOS subjects (n=3) with no change in placebo (n=3); pilot data, no menstrual/ovulatory benefit demonstrated; underpowered.
前往 PubMed
Therapeutic effects of chromium supplementation on women with polycystic ovarian syndrome: A systematic review and meta-analysis
結論：Chromium reduced BMI (WMD -0.87 kg/m2, 95%CI -1.55 to -0.18) but had no significant effect on weight, total cholesterol, LDL-C, HDL-C, triglycerides or hs-CRP in pooled analysis; effect on BMI driven by lower-dose subgroups.
前往 PubMed
L4a US FDA
謹慎
One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain. 來源↗
L4b EU EFSA
反對
The Panel concludes that there is no evidence of beneficial effects associated with chromium intake in healthy subjects ... no Average Requirement (AR) and Population Reference Intake (PRI) can be defined; chromium is not an essential nutrient. 來源↗
L4c UK NHS
謹慎
You should be able to get all the chromium you need by eating a varied and balanced diet. Around 25 micrograms of chromium a day should be enough for adults. Having 10mg or less a day of chromium from food and supplements is unlikely to cause any harm. 來源↗
L4d TW TFDA / 衛福部
支持
每日食用量中，其鉻之總含量不得高於200微克 來源↗
L4e WHO
未表態
Chromium[VI] is carcinogenic to humans (Group 1). Metallic chromium and chromium[III] compounds are not classifiable as to their carcinogenicity to humans (Group 3). 來源↗
L5a NIH Office of Dietary Supplements
謹慎
Research suggests that chromium supplementation reduces body weight and body fat percentage to a very small, but statistically significant, extent. However, these effects have little clinical significance. 來源↗
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
謹慎
L5d Harvard Health
反對
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽
台灣社群幾乎沒有「鉻（三價鉻）用於多囊性卵巢症候群」的真實討論。PTT（GoodPregnan/FITNESS/ChineseMed/WomenTalk）、Dcard（女孩/減肥/閒聊）的多囊主流補充品壓倒性集中在肌醇（inositol），其次 DHEA、CoQ11、維他命D，幾乎無人把鉻與多囊連結。鉻在台灣社群的討論脈絡是『控血糖/減重/胰島素阻抗』的一般保健（如 Dcard『有人聽過酵母鉻嗎』詢問穩血糖），而非針對多囊。針對此 intervention×condition 配對，社群實測心得稀少到無法形成有效訊號，屬冷門題，不予杜撰。
💬社群實感
無共識（社群幾乎無人把鉻用於多囊；多囊族群實測心得集中在肌醇而非鉻）
破解迷思 社群最常見的 2 個誤解
✓
事實因『多囊≈胰島素阻抗、鉻能穩血糖』而將控糖保健脈絡的鉻直接套用到多囊調理（社群此推論罕見且未經實測佐證）
✓
事實把鉻當作多囊『減重/降血糖神物』（鉻減重統合分析僅統計顯著、未達臨床顯著，Cochrane 對過重肥胖者亦無可靠減重實證）
- 健康生活型態與體重管理
- 複方口服避孕藥
- Metformin（二甲雙胍）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-pcos-INT-chromium-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "鉻（三價鉻）能改善多囊性卵巢症候群",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}